Tag - lecanemab

 
 

LECANEMAB

The price of Alzheimer's drug Lecanemab, codeveloped by Japanese drugmaker Eisai and U.S. industry peer Biogen, will be lowered to ¥97,277 for a 500-milligram bottle.
JAPAN / Science & Health
Aug 7, 2025
Japan approves price cut for Alzheimer's drug Lecanemab
The drug's price will be lowered to ¥97,277 for a 500-milligram bottle starting on Nov. 1.
The health ministry is expected to cut the official price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai and Biogen of the United States, by up to 15% from the current level of about ¥3 million per patient a year.
JAPAN / Science & Health
Jul 10, 2025
Japan to cut price of Alzheimer's drug lecanemab
The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million per patient a year.
Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
JAPAN / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer's drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
JAPAN / Science & Health
Sep 25, 2023
As Japan OKs Alzheimer's drug, issue of side effects comes into focus
There are big challenges ahead for the use of lecanemab, particularly on how to control side effects such as brain swelling and bleeding.
JAPAN / Science & Health
Aug 21, 2023
Japanese ministry panel gives OK to Alzheimer’s drug lecanemab
The panel’s endorsement will be followed by official approval by the health minister in coming days.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug's trial success raises hope for Alzheimer's prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.

Longform

Members of the nonprofit group Japan Youth Memorial Association search for the remains of dead soldiers in a cave in Okinawa Prefecture in February.
The long search for Japan’s lost soldiers